Elite Body Sculpture (AIRS): רווח למניה בשנים עשר החודשים האחרונים
High competition and the risk of new weight-loss drugs are weighing on AirSculpt Technologies (AIRS), yet the decline in pricing power within the premium segment is offset by the trailing 12-month earnings per share, where the latest figure stands at -0.13. The geographic reach of clinics across Europe, the US, and Canada ensures revenue stability, shielding the business from local consumption crises.
פילוחי נתונים אנליטיים מרוכזים עבור AirSculpt Technologies (AIRS)
Seamless logistics for medical equipment and consumables within AirSculpt Technologies (AIRS) clinics directly determine the stability of operating revenue. Analyzing the annual net income per share trend allows for a real-time assessment of margin erosion amid expensive borrowed capital, which is critical for evaluating the business's fundamental stability and mitigating the risks of frozen investments.
